Gene Therapy for Methylmalonic Acidemia
Author Information
Author(s): Chandler Randy J, Tsai Matthew S, Dorko Kenneth, Sloan Jennifer, Korson Mark, Freeman Richard, Strom Stephen, Venditti Charles P
Primary Institution: National Human Genome Research Institute, National Institutes of Health
Hypothesis
Can adenoviral-mediated gene delivery correct methylmalonyl-CoA mutase deficiency in human and murine cells?
Conclusion
Adenoviral-mediated gene delivery can effectively correct the enzymatic defect in methylmalonic acidemia in both murine models and human patients.
Supporting Evidence
- The adenoviral vector restored propionate metabolism in both murine and human cells.
- Infected human hepatocytes showed a significant increase in enzyme expression.
- The study demonstrated the potential for hepatocyte-directed gene therapy in treating methylmalonic acidemia.
Takeaway
Scientists used a virus to fix a problem in cells from people with a rare disease, showing it could help treat them in the future.
Methodology
Adenoviral vectors were used to deliver the methylmalonyl-CoA mutase gene to murine fibroblasts and human hepatocytes, followed by enzymatic and expression studies to assess correction.
Limitations
The study primarily used murine models and human cells from a single patient, which may limit generalizability.
Participant Demographics
Human hepatocytes were derived from a 5-year-old boy with methylmalonic acidemia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website